X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
humans (16) 16
cancer (9) 9
female (8) 8
male (7) 7
adult (6) 6
genetics (6) 6
middle aged (6) 6
aged (5) 5
genetic aspects (5) 5
oncology (5) 5
treatment outcome (5) 5
activation (4) 4
article (4) 4
gene expression (4) 4
immunology (4) 4
next generation sequencing (4) 4
physiological aspects (4) 4
rna interference (4) 4
signal transduction (4) 4
aged, 80 and over (3) 3
animals (3) 3
apoptosis (3) 3
biochemistry & molecular biology (3) 3
case-control studies (3) 3
disease (3) 3
gene expression profiling (3) 3
genetics & heredity (3) 3
genomes (3) 3
immunotherapy (3) 3
mechanisms (3) 3
multiple sclerosis - genetics (3) 3
multiple sclerosis - immunology (3) 3
mutation (3) 3
neurosciences (3) 3
nf-kappa b - metabolism (3) 3
proteins (3) 3
therapy (3) 3
tumors (3) 3
young adult (3) 3
15-year follow-up (2) 2
abridged index medicus (2) 2
adolescent (2) 2
aggregatibacter actinomycetemcomitans (2) 2
aging (2) 2
allergy and immunology (2) 2
antibodies, monoclonal - pharmacology (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoeε4 (2) 2
articles (2) 2
association (2) 2
b-lymphocytes - immunology (2) 2
b-lymphocytes - metabolism (2) 2
b7-h1 antigen - antagonists & inhibitors (2) 2
b7-h1 antigen - immunology (2) 2
bevacizumab (2) 2
bladder cancer (2) 2
bladder-cancer (2) 2
care and treatment (2) 2
cathepsin-c gene (2) 2
cell biology (2) 2
cell differentiation (2) 2
cell line, tumor (2) 2
cells (2) 2
cells, cultured (2) 2
clear cell-type renal cell carcinoma (2) 2
cognition (2) 2
cohort studies (2) 2
comparative analysis (2) 2
ctla-4 blockade (2) 2
cytokines (2) 2
dentistry (2) 2
dentistry, oral surgery & medicine (2) 2
development and progression (2) 2
disease models, animal (2) 2
drosophila (2) 2
ebv transformation (2) 2
expression (2) 2
follow-up studies (2) 2
functional genomics (2) 2
gene expression regulation (2) 2
gene-expression (2) 2
genetic predisposition to disease (2) 2
genetic research (2) 2
genomics (2) 2
i-kappa b kinase - immunology (2) 2
immune checkpoint (2) 2
immunology and allergy (2) 2
inflammation (2) 2
internal medicine (2) 2
ligands (2) 2
longitudinal studies (2) 2
lymphoblastoid cell line (2) 2
lymphocytes (2) 2
medical prognosis (2) 2
medical research (2) 2
medicine, research & experimental (2) 2
metastases (2) 2
metastasis (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Bioindicators | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma | Index Medicus
Journal Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. 3602 - 3602
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 04/2019, Volume 79, Issue 7, pp. 1493 - 1506
Checkpoint inhibitors like anti-PD1/PD-L1 have demonstrated significant therapeutic efficacy in a subset of patients partly through reinvigoration of CD8 T... 
ACTIVATION | PHAGOCYTOSIS | ONCOLOGY | NITRIC-OXIDE | TUMOR-ASSOCIATED MACROPHAGES | ANTIBODY | IMMUNE CHECKPOINT | BLOCKADE | CANCER | POLARIZATION | T-CELLS
Journal Article
Neurobiology of aging, ISSN 0197-4580, 3/2015, Volume 36, Issue 3, pp. 1435 - 1438
Although numerous genetic variants affecting aging and mortality have been identified, e.g. APOE ε4, the genetic component influencing cognitive aging has not... 
APOEε4 | genetics | aging | cognition | next generation sequencing | personalized medicine
Journal Article
BMC Genomics, ISSN 1471-2164, 2012, Volume 13, Issue 1, p. 477
Abstract Background A detailed analysis of whole genomes can be now achieved with next generation sequencing. Epstein Barr Virus (EBV) transformation is a... 
EBV transformation | Lymphoblastoid cell line | Genetics | Next generation sequencing
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 02/2017, Volume 35, Issue 6, pp. 326 - 326
Conference Proceeding
Cell Death and Differentiation, ISSN 1350-9047, 2019
Emerging research suggests that multiple tumor compartments can influence treatment responsiveness and relapse, yet the search for therapeutic resistance... 
Journal Article